Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome
Objectives: To investigate the effect of systemic infliximab therapy on tear function tests and the ocular surface in patients with Sjögren’s syndrome secondary to various autoimmune diseases. Materials and Methods: This prospective study included 22 eyes of 22 patients with Sjögren’s syndrome who...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Yayinevi
2015-08-01
|
Series: | Türk Oftalmoloji Dergisi |
Subjects: | |
Online Access: | http://www.oftalmoloji.org/article_9129/Effect-Of-Systemic-Infliximab-Therapy-In-Patients-With-sjogrens-Syndrome |
id |
doaj-c704d97ef4fa4242a1b93c5f1219655f |
---|---|
record_format |
Article |
spelling |
doaj-c704d97ef4fa4242a1b93c5f1219655f2020-11-25T00:34:23ZengGalenos YayineviTürk Oftalmoloji Dergisi1300-06592147-26612015-08-0145413814110.4274/tjo.48379 Effect of Systemic Infliximab Therapy in Patients with Sjögren’s SyndromeElif Betül Türkoğlu0Serpil Tuna1 Sevil Alan2Akdeniz University Faculty of Medicine, Department of Ophthalmology, Antalya, TurkeyAkdeniz University Faculty of Medicine, Department of Physical Therapy and Rehabilitation, Antalya, TurkeyAkdeniz University Faculty of Medicine, Department of Dermatology, Antalya, TurkeyObjectives: To investigate the effect of systemic infliximab therapy on tear function tests and the ocular surface in patients with Sjögren’s syndrome secondary to various autoimmune diseases. Materials and Methods: This prospective study included 22 eyes of 22 patients with Sjögren’s syndrome who began treatment with systemic infliximab. Tear film break-up time (TBUT), anesthetized Schirmer’s 1 test, fluorescein staining test, and Ocular Surface Disease Index (OSDI) scores were recorded before treatment and in the 3rd and 6th months of treatment. Results: In the 3rd month of infliximab therapy, no significant changes were observed in Schirmer’s values, TBUT, fluorescein staining, or OSDI scores (p=0.260, p=0.357, p=0.190 and p=0.07, respectively). In the 6th month of infliximab therapy, no significant changes were observed in TBUT, fluorescein staining, Schirmer’s value or OSDI scores (p=0.510, p=0.320, p=0.220 and p=0.344, respectively). Conclusion: Infliximab therapy, which is commonly used in systemic autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis, did not show a positive effect on ocular surface and tear function tests. (Turk J Ophthalmol 2015; 45: 138-141)http://www.oftalmoloji.org/article_9129/Effect-Of-Systemic-Infliximab-Therapy-In-Patients-With-sjogrens-SyndromeDry eyeinfliximabSjögren’s syndrometumor necrosis factor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elif Betül Türkoğlu Serpil Tuna Sevil Alan |
spellingShingle |
Elif Betül Türkoğlu Serpil Tuna Sevil Alan Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome Türk Oftalmoloji Dergisi Dry eye infliximab Sjögren’s syndrome tumor necrosis factor |
author_facet |
Elif Betül Türkoğlu Serpil Tuna Sevil Alan |
author_sort |
Elif Betül Türkoğlu |
title |
Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome |
title_short |
Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome |
title_full |
Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome |
title_fullStr |
Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome |
title_full_unstemmed |
Effect of Systemic Infliximab Therapy in Patients with Sjögren’s Syndrome |
title_sort |
effect of systemic infliximab therapy in patients with sjögren’s syndrome |
publisher |
Galenos Yayinevi |
series |
Türk Oftalmoloji Dergisi |
issn |
1300-0659 2147-2661 |
publishDate |
2015-08-01 |
description |
Objectives: To investigate the effect of systemic infliximab therapy on tear function tests and the ocular surface in patients with
Sjögren’s syndrome secondary to various autoimmune diseases.
Materials and Methods: This prospective study included 22 eyes of 22 patients with Sjögren’s syndrome who began treatment with
systemic infliximab. Tear film break-up time (TBUT), anesthetized Schirmer’s 1 test, fluorescein staining test, and Ocular Surface Disease
Index (OSDI) scores were recorded before treatment and in the 3rd and 6th months of treatment.
Results: In the 3rd month of infliximab therapy, no significant changes were observed in Schirmer’s values, TBUT, fluorescein staining,
or OSDI scores (p=0.260, p=0.357, p=0.190 and p=0.07, respectively). In the 6th month of infliximab therapy, no significant changes
were observed in TBUT, fluorescein staining, Schirmer’s value or OSDI scores (p=0.510, p=0.320, p=0.220 and p=0.344, respectively).
Conclusion: Infliximab therapy, which is commonly used in systemic autoimmune diseases such as rheumatoid arthritis, Crohn’s
disease, ulcerative colitis, and ankylosing spondylitis, did not show a positive effect on ocular surface and tear function tests. (Turk J
Ophthalmol 2015; 45: 138-141) |
topic |
Dry eye infliximab Sjögren’s syndrome tumor necrosis factor |
url |
http://www.oftalmoloji.org/article_9129/Effect-Of-Systemic-Infliximab-Therapy-In-Patients-With-sjogrens-Syndrome |
work_keys_str_mv |
AT elifbetulturkoglu effectofsystemicinfliximabtherapyinpatientswithsjogrenssyndrome AT serpiltuna effectofsystemicinfliximabtherapyinpatientswithsjogrenssyndrome AT sevilalan effectofsystemicinfliximabtherapyinpatientswithsjogrenssyndrome |
_version_ |
1725313772500811776 |